KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Receivables - Accured (2022 - 2025)

Arbutus Biopharma's Revenue - Other history spans 5 years, with the latest figure at $721000.0 for Q2 2017.

  • For Q2 2017, Revenue - Other rose 160.29% year-over-year to $721000.0; the TTM value through Jun 2017 reached $1.8 million, down 81.87%, while the annual FY2017 figure was $10.0 million, 693.82% up from the prior year.
  • Receivables - Accured for Q3 2025 was $300000.0 at Arbutus Biopharma, up from $100000.0 in the prior quarter.
  • Across five years, Receivables - Accured topped out at $600000.0 in Q4 2022 and bottomed at $100000.0 in Q2 2025.
  • The 4-year median for Receivables - Accured is $450000.0 (2022), against an average of $425000.0.
  • The largest annual shift saw Revenue - Other soared 705.67% in 2015 before it crashed 97.62% in 2016.
  • A 5-year view of Revenue - Other shows it stood at $5.0 million in 2013, then plummeted by 79.69% to $1.0 million in 2014, then skyrocketed by 705.67% to $8.2 million in 2015, then plummeted by 97.62% to $196000.0 in 2016, then skyrocketed by 267.86% to $721000.0 in 2017.
  • Per Business Quant, the three most recent readings for ABUS's Revenue - Other are $721000.0 (Q2 2017), $217000.0 (Q1 2017), and $196000.0 (Q4 2016).